Corcept Therapeutics (CORT) Stock Price, Quote & News

Company Profile

Corcept Therapeutics Incorporated engages in discovery and development of medication for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also develop...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 327 3270

Website: www.corcept.com

Address:

101 Redwood Shores Parkway, Redwood City, United States

gucag006 Feb. 3 at 9:08 PM

$CORT For people who like to hear about and can handle the truth. Apple-to-apple comparison of reported liver injury during their perspective clinical trials (All from Gemini 3 AI): Recorlev (SONICS & LOGICS trials) Peak ALT/AST > 3x ULN - 13% to 15% of patients Peak ALT/AST > 5x ULN - 3% of patients Relacorilant (GRACE & GRADIENT trials) Peak ALT/AST > 3x ULN - 11% of patients Peak ALT/AST > 5x ULN - 4% of patients Trial cohorts sizes Recorlev: SONICS ~ 94, LOGICS ~ 79 (44 randomized) Relacorilant: GRADIENT ~ 137, GRACE ~ 152 (68 randomized) I encourage you to check these #'s using your preferred AI's. Note: ULN = "Upper Limit of Normal"

1 · Reply

gucag006 Feb. 3 at 8:16 PM

$CORT Q4/25 ER will be on 2/25/26 after market close. I am eager to hear what he has to say.

1 · Reply

BiotechDrTrader Feb. 3 at 6:22 PM

$CORT hanging in there despite a mixed day in biotech and a down day in the market overall - can't wait for PROC pdufa

0 · Reply

TymeTryethTroth Feb. 3 at 2:26 PM

$XERS https://seekingalpha.com/article/4865261-xeris-biopharma-strong-recorlev-momentum-and-pipeline-opportunity?share_source=shared_news $BMRN $RARE $LLY $CORT (Comps mentioned in article)

0 · Reply

SuperGreenToday Feb. 2 at 7:37 PM

$CORT Share Price: $40.12 Contract Selected: May 15, 2026 $40 Calls Buy Zone: $4.93 – $6.09 Target Zone: $8.07 – $9.86 Potential Upside: 55% ROI Time to Expiration: 101 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

BuyThisOne Feb. 1 at 3:12 PM

$XERS $CORT Increased awarness is good for investors and patients alike. https://csrf.net/

0 · Reply

BuyThisOne Feb. 1 at 3:11 PM

$XERS $CORT Pretty cool story. Seems Strongbridge(Merged with Xeris) followed a similar path with Ketoconazole by purifying it into the levo enantiomer and getting it approved for Cushings syndrome for a relatively low cost. It is important when investing to not only worry about a rising stock price but also the people who's lives have been drastically changed by these medications. The work Corcept and now Xeris is doing to change how these patients are identified allows more people to find a path to having a life they actually want to be alive for. The focus here should be on posting facts instead of attacking each other with outright falsehoods or half-truths. https://kffhealthnews.org/news/how-a-drugmaker-turned-the-abortion-pill-into-a-rare-disease-profit-machine/#:~:text=When%20the%20Food%20and%20Drug,1%2C000%20patients%20in%20the%20U.S.)

0 · Reply

BuyThisOne Feb. 1 at 2:49 PM

$XERS $CORT At the end of the day, the main goal should be access and options for patients needing medicine for these awful conditions. Corcept did a disservice to both themselves and patients by not heeding the FDA's warnings. Patients currently have 3 options and one of them has a generic which is great to help reduce costs over time. This market still has a lot of room to grow as more patients are identified. I could care less about CORT's stock price or their revenue as I am not an investor. It does look like it could 10x from here in 10 years just like XERS will most likely do as well in 5 to 10 years. Maybe split your investment across these 2 if you are worried one way or the other.

1 · Reply

Alon_R Feb. 1 at 1:29 PM

$XERS $CORT Recorlev's upside is substantial, to say the least, because it is a direct cortisol-lowering treatment and therefore a primary therapy, addressing approximately 75–80% of the patient population. The growth potential there is significant. Korlym, by contrast, is a secondary treatment, addressing roughly 20–25% of patients, primarily those who cannot tolerate direct cortisol-lowering therapies due to issues such as liver toxicity or other contraindications. In other words, Recorlev addresses the majority of the treatable Cushing's patient population (roughly ~75–80%), as it directly lowers cortisol and fits first-line treatment paradigms, while Korlym is more naturally positioned for a smaller subset (~25–30%) of patients who cannot tolerate or do not respond to direct cortisol-lowering therapies. And they are not even in competition with each other, the 20-25% that can not tolerate Recorlev/Direct cortisol-lowering, will go naturally to Korlym/etc. Simple equation.

0 · Reply

gucag006 Feb. 1 at 12:31 PM

$XERS $CORT Both Korlym and Recorlev have to be taken continuously. For Recorlev patients, 13% will suffer liver injury, but not Korlym patients. Liver transplant has been reported among Recorlev patients.

2 · Reply

Corcept Therapeutics Incorporated Investigated on Behalf of Investors - Contact the DJS Law Group to Discuss Your Rights - CORT

Feb 2, 2026, 4:41 AM EST - 1 day ago

CORT Investors Have Opportunity to Join Corcept Therapeutics Incorporated Fraud Investigation with the Schall Law Firm

Jan 30, 2026, 8:32 PM EST - 4 days ago

Hagens Berman Investigating Corcept Therapeutics (CORT): Shares Fall After Report That FDA Warned Against Relacorilant Drug Application Filing

Jan 30, 2026, 3:28 PM EST - 4 days ago

Corcept Therapeutics (CORT) Shares Fall Again Amid Report FDA Warned Several Times Not to Submit Relacorilant Drug Application – Hagens Berman

Jan 30, 2026, 2:20 PM EST - 4 days ago

Berman Tabacco Announces Investigation of Corcept Therapeutics Incorporated (NASDAQ: CORT) Concerning FDA New Drug Application

Jan 30, 2026, 10:36 AM EST - 4 days ago

Corcept shares tumble after FDA letter reveals warnings before drug rejection

Jan 30, 2026, 10:13 AM EST - 4 days ago

Corcept Therapeutics Investigated for Securities Fraud Following Report of FDA Warnings; Shareholders Should Contact Block & Leviton To Recover Losses

Jan 22, 2026, 11:12 AM EST - 12 days ago

Corcept Therapeutics Experimental Lead Drug Cuts Death Risk By 35% In Advanced Ovarian Cancer Patients, Stock Jumps

Jan 22, 2026, 8:13 AM EST - 12 days ago

Corcept's cancer drug meets main goal in late-stage trial

Jan 22, 2026, 8:00 AM EST - 12 days ago

Overall Survival Primary Endpoint Met in Corcept's Pivotal Phase 3 ROSELLA Trial of Relacorilant in Patients with Platinum-Resistant Ovarian Cancer

Jan 15, 2026, 10:31 AM EST - 19 days ago

These under-the-radar stocks combine fast growth with big upside potential

AGYS ASTH BBT CTRE DCOM DOCN ENVA

Jan 14, 2026, 9:52 PM EST - 20 days ago

Corcept Therapeutics Incorporated Investigated on Behalf of Investors - Contact the DJS Law Group to Discuss Your Rights – CORT

Jan 14, 2026, 11:56 AM EST - 20 days ago

Corcept Therapeutics (CORT) Faces Investor Scrutiny Amid Receipt of FDA Complete Response Letter For Relacorilant, Shares Tank 50% - Hagens Berman

Jan 13, 2026, 9:43 AM EST - 21 days ago

CORT INVESTIGATION: Corcept Therapeutics Investors Should Contact Block & Leviton LLP To Potentially Recover Losses

Jan 12, 2026, 12:11 PM EST - 22 days ago

Scott+Scott Attorneys at Law LLP Announces Its Investigation Into Corcept Therapeutics Incorporated (CORT)

Jan 9, 2026, 3:24 PM EST - 25 days ago

Corcept Therapeutics (CORT) Faces Investor Scrutiny Amid Receipt of FDA Complete Response Letter For Relacorilant, Shares Tank 50% – Hagens Berman

Jan 9, 2026, 10:00 AM EST - 25 days ago

Scott+Scott Attorneys at Law LLP Reminds Investors of Its Investigation Into Corcept Therapeutics Incorporated (NASDAQ: CORT)

Jan 7, 2026, 2:33 PM EST - 27 days ago

Scott+Scott Attorneys at Law LLP Alerts Investors of Its Investigation Into Corcept Therapeutics Incorporated (CORT)

Jan 4, 2026, 7:08 AM EST - 4 weeks ago

Corcept Therapeutics: Despite FDA Blind Side, Relacorilant Remains A Viable Drug

Dec 31, 2025, 4:02 PM EST - 4 weeks ago

Why Corcept Therapeutics stock crashed today and what comes next?

Dec 31, 2025, 12:31 PM EST - 4 weeks ago

Corcept Therapeutics Shares Drop 50% After FDA Rejects Drug

Dec 31, 2025, 8:05 AM EST - 4 weeks ago

US FDA declines to approve Corcept's drug for rare hormonal disorder

Dec 31, 2025, 8:00 AM EST - 4 weeks ago

Corcept Receives Complete Response Letter for Relacorilant as a Treatment for Patients with Hypercortisolism

Dec 22, 2025, 11:41 AM EST - 6 weeks ago

Corcept Therapeutics' Upcoming FDA Decision: Is A CRL Likely?

Nov 4, 2025, 7:26 PM EST - 3 months ago

Corcept Therapeutics Incorporated (CORT) Q3 2025 Earnings Call Transcript

Nov 4, 2025, 4:05 PM EST - 3 months ago

Corcept Therapeutics Announces Third Quarter Financial Results, Oncology Development Programs and Provides Corporate Update

Oct 28, 2025, 4:05 PM EDT - 3 months ago

Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call

Oct 19, 2025, 5:15 AM EDT - 3 months ago

Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment

Oct 15, 2025, 9:13 AM EDT - 3 months ago

Corcept Transition To New Specialty Pharmacy Well Underway

Oct 14, 2025, 8:00 AM EDT - 4 months ago

Corcept Submits Marketing Authorization Application to European Medicines Agency for Relacorilant as a Treatment for Patients with Platinum-Resistant Ovarian Cancer

Oct 1, 2025, 9:00 AM EDT - 4 months ago

Curant Rare Announces Pharmacy Partnership with Corcept Therapeutics

Sep 29, 2025, 7:11 AM EDT - 4 months ago

4 Biotechnology Stocks That Outshine In Momentum Amid Strong Technicals

ARWR ASMB ATRA

Sep 26, 2025, 12:06 PM EDT - 4 months ago

Corcept Primed For An Upside EPS Surprise

Sep 22, 2025, 2:30 PM EDT - 4 months ago

Corcept to Present New Late-Breaking Data From Pivotal ROSELLA Trial of Relacorilant in Platinum-Resistant Ovarian Cancer at ESMO 2025

Sep 15, 2025, 2:18 PM EDT - 5 months ago

11 fast-growing small-cap stocks that could get a boost from the Fed's next move

AGYS ASTH ENVA GSHD HASI HRMY KNTK

Sep 10, 2025, 8:00 AM EDT - 5 months ago

FDA Files Corcept's New Drug Application for Relacorilant as a Treatment for Patients with Platinum-Resistant Ovarian Cancer

Aug 7, 2025, 9:54 PM EDT - 6 months ago

Corcept's Q2 Demand Grows 60%, Penetrating Large Type 2 Diabetes Market Early

Aug 1, 2025, 2:32 PM EDT - 6 months ago

Corcept Therapeutics Incorporated (CORT) Q2 2025 Earnings Call Transcript

Jul 31, 2025, 4:05 PM EDT - 6 months ago

Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update

Jul 24, 2025, 4:05 PM EDT - 6 months ago

Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call

gucag006 Feb. 3 at 9:08 PM

1 · Reply

gucag006 Feb. 3 at 8:16 PM

$CORT Q4/25 ER will be on 2/25/26 after market close. I am eager to hear what he has to say.

1 · Reply

BiotechDrTrader Feb. 3 at 6:22 PM

$CORT hanging in there despite a mixed day in biotech and a down day in the market overall - can't wait for PROC pdufa

0 · Reply

TymeTryethTroth Feb. 3 at 2:26 PM

$XERS https://seekingalpha.com/article/4865261-xeris-biopharma-strong-recorlev-momentum-and-pipeline-opportunity?share_source=shared_news $BMRN $RARE $LLY $CORT (Comps mentioned in article)

0 · Reply

SuperGreenToday Feb. 2 at 7:37 PM

0 · Reply

BuyThisOne Feb. 1 at 3:12 PM

$XERS $CORT Increased awarness is good for investors and patients alike. https://csrf.net/

0 · Reply

BuyThisOne Feb. 1 at 3:11 PM

0 · Reply

BuyThisOne Feb. 1 at 2:49 PM

1 · Reply

Alon_R Feb. 1 at 1:29 PM

0 · Reply

gucag006 Feb. 1 at 12:31 PM

2 · Reply

gucag006 Feb. 1 at 12:25 PM

$XERS $CORT (Gemini) 2. Why Korlym is Holding Steady The expected "threat" from Recorlev has been mitigated by a few key factors: Different Mechanisms of Action: Korlym is a cortisol receptor blocker (it stops the hormone from working), while Recorlev is a steroidogenesis inhibitor (it stops the body from making cortisol). Doctors often view them as complementary or for different patient profiles rather than direct "either/or" substitutes. Market Expansion: Increased awareness and better diagnostic tools are identifying more Cushing’s patients than ever before. This "rising tide" is lifting both boats. Generic Buffer: Corcept’s launch of its own authorized generic of Korlym has helped it retain budget-conscious patients who might have otherwise switched to newer or different therapies.

0 · Reply

gucag006 Feb. 1 at 12:21 PM

$XERS $CORT (Gemini) While Recorlev (marketed by Xeris Biopharma) has seen explosive growth since its 2022 launch, it has not "cannibalized" Korlym’s sales in a way that has led to a decline. Instead, both drugs are growing simultaneously as the overall market for Cushing’s syndrome treatments expands. Here is a breakdown of how the competition is playing out as of early 2026: 1. The Financial Reality Despite Recorlev's rapid adoption, Korlym (and its authorized generic) continues to hit record revenues. Korlym (Corcept): In 2024, Korlym generated $675 million (a 40% increase over 2023). For 2025, Corcept projected revenues between $800 million and $850 million, showing that Korlym's market position remains dominant. Recorlev (Xeris): Recorlev is growing even faster by percentage, with 2025 revenues reaching approximately $139 million (a 100%+ year-over-year increase).

0 · Reply

Nizmeister Feb. 1 at 5:33 AM

$XERS vs $CORT Korlym sales Year 1: $3.3 million Year 2: $10.4 million Year 3: $26.6 million Year 4: $50.3 million Recorlev sales Year 1: $7.4 million Year 2: $29.5 million Year 3: $64.3 million Year 4: $139 million Recorlev growing much more aggresively and will be the dominant therapy sooner than later. expanded sales force will speeds things up.

0 · Reply

CakeorDeath2 Jan. 31 at 6:57 PM

$AQST one note just to be objective. It looks like $CORT ankounced the December CRL before it was public. The letter is dated Dec 30 but the announcement by the company was at 8 on Dec 31 and there was no press before then. May have something to do with the CRL last summer.

3 · Reply

AnalyticalDog Jan. 31 at 4:13 PM

$AQST no the FDA does not post CRL’s immediately. In the case of $CORT a CRL was received in December. They did not publish the CRL until January 29th… No reason to assume approval because of silence.

2 · Reply

gucag006 Jan. 31 at 9:26 AM

$CORT Okay, the reality of Relacorilant CRL has completely soaked in. Most likely additional trial is needed pushing resubmission and approval from late 2027 to 2028. Let's scale back our expectation accordingly. Korlym should support a SP around $50 to $60. Relaorilant+chemo for PROC will be approved by 7/11/26, which should add $50 to the SP in 2027. Relacorilant for Cushing will be approved in 2028, which should add another $100 to the SP in 2028/29. Dazucorilant for ALS will be approved in 2028, which should add another$100 to the SP in 2028/29. From these 4 drugs, TP of $300 is realistic. There are other cancer drugs under clinical trials, and will add $100's to the SP in 3 to 5 years.

1 · Reply

mikesterz7 Jan. 31 at 3:44 AM

$CORT FDA refused to approve Corcept’s Relacorilant for hypercortisolism in December, citing insufficient proof of effectiveness.

0 · Reply

gucag006 Jan. 31 at 1:38 AM

$CORT Recorlev vs. Relacorilant (3): Form Gemini, we didn't see liver injury as one of the reasons for the FDA CRL as other so-called experts sent by Xeris Biopharma (XERS) shouted out loudly here. "Enriched" cohorts is not the poor design and/or management's fault, but the natural progression of the trial. The small sample size is more ridiculous: Recorlev: SONICS ~ 94, LOGICS ~ 79 w/ 44 randomized. Relacorilant: GRACE ~ 152, GRADIENT ~ 137 Even if 45% made to the randomized phase, it was 68 in GRACE, which is 24 more than in LOGICS. So, FDA god, what is your standard to call it "small?" So, I got it, the FDA god wants to deny or delay Relacorilant for Cushing by another 18 to 24 months, and in the meantime, 1) Force Cushing sufferers to take Korlym with low risk or Recorlev with 13% risk of liver injury and some of them would require an organ transplant, and 2) For all other Cushing sufferers, especially for the female population, go without treatment for at least next two years.

2 · Reply

gucag006 Jan. 31 at 1:10 AM

$CORT Recorlev vs. Relacorilant according to Gemini (2): 2. The Hurdle: Why Relacorilant was Denied: In contrast, the FDA issued a Complete Response Letter (CRL) for relacorilant on 12/30/25. The issue wasn't necessarily that the drug was "dangerous," but that the data was seen as inconclusive: - "Enriched" Population Problem: In the pivotal GRACE trial, the FDA noted that while the primary endpoint was met, it was conducted in a "highly enriched" population (only 45% of patients made it to the randomized withdrawal phase). The FDA argued this "likely overestimates the treatment effect" and doesn't represent for the general patient population. - "Failed" Confirmatory Trial: The GRADIENT trial, failed its primary endpoint. Corcept tried to show success through a subgroup - dismissed by FDA as "unreliable" due to small sample & missing data. - Prior Warnings: FDA actually warned Corcept multiple times during development that their trial designs might be insufficient to prove effectiveness.

0 · Reply

gucag006 Jan. 31 at 1:02 AM

$CORT I asked Gemini AI "Is FDA fair to approve recorlev but deny relacorilant?" Here is the results (1): 1. The Evidence: Why Recorlev was Approved Recorlev (levoketoconazole) was approved in December 2021. The FDA's decision was based on two Phase 3 studies (SONICS and LOGICS) that showed clear, statistically significant results: - Demonstrated Efficacy: It successfully lowered and normalized urinary free cortisol (UFC) levels in a consistent manner across the study population. - Clear Benefit-Risk: While Recorlev has serious risks (like liver toxicity and heart rhythm issues), the FDA determined these could be managed through a REMS program (Risk Evaluation and Mitigation Strategy) because the drug’s ability to control cortisol was undeniable.

0 · Reply

AmateurTrader212 Jan. 30 at 11:14 PM

$AQST Given what just happened to $CORT with its CRL letter published by FDA and which contradicts the reasons provided by management for the rejection, AQST is in a bind. How to best spin the CRL with publication imminent?!? Can we continue to hide safety concerns?

0 · Reply

gucag006 Jan. 30 at 10:51 PM

$CORT Absolutely, from Gemini 3 AI (note the "Gold Standard"): In the world of oncology, a 30% reduction in the risk of death (often reported as a Hazard Ratio of 0.70) is generally considered clinically significant and is often the "gold standard" target for new, practice-changing therapies. 1. Relative vs. Absolute Gain This is the most critical distinction to understand when reading about cancer drug breakthroughs. Relative Risk (The 30%): This tells you how much better the new drug is compared to the old one. If the "hazard" of dying at any given moment is 30% lower, the drug is considered very potent. Absolute Gain (The "Actual Time"): A 30% reduction in risk looks very different depending on the type of cancer: In aggressive, late-stage cancer: If the median survival is 6 months, a 30% risk reduction might only extend life by ~2 months. In slower-growing or early-stage cancer: If the median survival is 10 years, that same 30% reduction could mean 3 extra years of life.

0 · Reply

Market Cap	4.19B
Revenue (ttm)	675.04M
Net Income (ttm)	141.21M
EPS (ttm)	N/A
PE Ratio	50.69
Forward PE	52.95
Profit Margin	20.92%
Debt to Equity Ratio	0.00

Volume	1,752,300
Avg Vol	2,090,862
Day's Range	N/A - N/A
Shares Out	105.19M
Stochastic %K	38%
Beta	0.23
Analysts	Sell
Price Target	$94.20